MeTC7
MeTC7 structure
|
Common Name | MeTC7 | ||
|---|---|---|---|---|
| CAS Number | 1817841-22-7 | Molecular Weight | 618.65 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H48BrN3O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MeTC7MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects[1]. |
This table lists Chinese names, IUPAC names and various aliases of this chemical substance.
| Name | MeTC7 |
|---|
This table contains bioactivity, target information and biological‑assay experimental data of this compound.
| Description | MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 2.9 μM (VDR)[1]. |
| In Vitro | MeTC7 (compound 5) shows potent VDR inhibition activity with an IC50 value of 2.9 μM[1]. MeTC7 disrupts the VDR-Ligand-binding domain in Silico[1]. MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line[1]. MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage[1]. Western Blot Analysis[1] Cell Line: 2008 cells Concentration: 250 nM Incubation Time: 18, 12 h Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells. Cell Viability Assay[1] Cell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM Incubation Time: 24 h Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines. |
| In Vivo | MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo[1]. Animal Model: Mice[1] Dosage: 10 mg/kg Administration: IP Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma. |
This table shows physicochemical parameters including melting point, boiling point, density, solubility and optical rotation. Missing data is marked as N/A.
| Molecular Formula | C32H48BrN3O4 |
|---|---|
| Molecular Weight | 618.65 |
| InChIKey | LBFDLJSQMPCWKK-YMNKQYQVSA-N |
| SMILES | CC(C)CCCC(C)C1CCC2C1(C)CCC1C23C=CC2(CC(OC(=O)CBr)CCC12C)n1c(=O)n(C)c(=O)n13 |
This section contains frequently‑asked‑questions about this compound, including basic parameters, properties, storage conditions and corresponding answers.
| Q: What is the English name of MeTC7? |
| A: The English name of MeTC7 is MeTC7. |
| Q: What is the molecular formula of MeTC7? |
| A: Molecular formula of MeTC7 is C32H48BrN3O4. |
| Q: What are the uses of MeTC7? |
| A: Main uses of MeTC7: MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects[1]. |
| Q: What is the InChIKey of MeTC7? |
| A: InChIKey of MeTC7 is LBFDLJSQMPCWKK-YMNKQYQVSA-N. |
| Q: What is the CAS number of MeTC7? |
| A: CAS number of MeTC7 is 1817841-22-7. |
| Q: What is the molecular weight of MeTC7? |
| A: Molecular weight of MeTC7 is 618.65. |
| Q: What is the Chinese name of 1817841-22-7? |
| A: Chinese name of 1817841-22-7 is 1817841-22-7. |
| Q: What is the SMILES notation of MeTC7? |
| A: SMILES notation of MeTC7 is CC(C)CCCC(C)C1CCC2C1(C)CCC1C23C=CC2(CC(OC(=O)CBr)CCC12C)n1c(=O)n(C)c(=O)n13. |
This table lists manufacturers and suppliers of this compound, including vendor names and product supply reference information.
| Shanghai Nianxing Industrial Co., Ltd |